36 results about "Insulin treatments" patented technology

The present invention relates to insulin and / or an insulin analogue conjugate, and a use thereof, wherein the insulin and / or insulin analogue have improved in vivo durability and stability by linking the same with an Fc region of immunoglobulin. The insulin and / or an insulin analogue conjugate of the present invention show an in vivo activity similar to that of insulin. In addition, the insulin and / or insulin analogue conjugate of the present invention are long-acting formulations of insulin and / or the analogue thereof, in which serum half-life is remarkably increased, and therefore, the present invention provides remarkable insulin and / or an insulin analogue conjugate, which do not induce hypoglycemia, a drawback of insulin treatment.

The present invention relates to an insulin conjugate having improved in vivo duration and stability, which is prepared by covalently linking insulin with an immunoglobulin Fc region via a non-peptidyl polymer, a long-acting formulation comprising the same, and a preparation method thereof. The insulin conjugate of the present invention maintains in vivo activity of the peptide at a relatively high level and remarkably increases the serum half-life thereof, thereby greatly improving drug compliance upon insulin treatment.

The invention relates to an individualized insulin treatment pump (CSII) assisted by a CGMS. The individualized insulin treatment pump comprises an insulin pump body, a communication module, a data processing module and an infusion actuator. The insulin pump body receives a treatment scheme obtained by the data processing module and controls the infusion actuator to infuse insulin according to the treatment scheme. The communication module obtains data from the CGMS and the insulin pump body so as to allow the data processing module to form the treatment scheme. The invention further relates to a basic infusion rate optimization method based on the insulin treatment pump. By the adoption of the individualized insulin treatment pump and the basic infusion rate optimization method of the individualized insulin treatment pump, a model can be formed according to real-time feedback blood glucose data of each patient, and the basic infusion amount is judged and optimized by stimulating and adjusting the basic infusion rate of the insulin.

A system for optimizing a patient's insulin treatment, comprising a drug delivery device (320) with an identifier representing information for a specific drug contained in a reservoir. An accessory device (310) comprises a blood glucose meter (BGM) and a processor programmed to determine for at least two pre-defined specific drugs a recommendation for an amount of the given drug based on a blood glucose value. The recommendation for a given pre-defined drug can be calculated when the corresponding identifier has been captured with the accessory device in a current mounted state, the recommended dose being calculated based on one or more blood glucose values, one or more patient specific parameters as well as parameters for the identified specific type of drug.

The invention provides a portable multifunctional intelligent insulin pump which has high degree of intensification and is based on the modern electronic technology, and a control module thereof, andthe intelligent insulin pump is composed of an intelligent insulin pump body, a blood glucose detection sensor which is directly connected therewith and an infusion actuator. The change of the blood glucose is tracked by dynamic monitoring of the blood glucose level of a user, thus infusing the insulin for the treatment of diabetes. The insulin pump body is connected with a mobile phone by a communication protocol, and the user can control the infusion amount by the mobile phone. The errors of the monitoring of the blood glucose are calculated according to the characteristics of the self bloodglucose and the basic amount of the normal blood glucose of the user, thus establishing the control model of the infusion pump. When the blood glucose content exceeds the allowable range, the controller emits a command, a drive mechanism allows the insulin in a liquid storage tank to pass a pipeline, and the insulin is infused to the body of the user by utilizing the infusion actuator. With the effects of waterproof, corrosion resistance, vibration resistance and low power consumption, the invention is the complete and integrated novel insulin treatment instrument which does not affect the normal life and works normally.

The present invention relates to an insulin and / or insulin analogue complex and a use thereof, the insulin and / or insulin analogue complex having improved in-vivo persistence and stability by connecting the insulin and / or insulin analogue with the Fc region of immunoglobulin. The insulin and / or insulin analogue complex according to the present invention is a groundbreaking insulin and / or insulin analogue complex which is a long-acting formulation of insulin and / or insulin analogue showing activities similar to insulin in the body and having a remarkedly increased half-life in the blood, and which does not induce hypoglycemia which is a demerit of insulin treatment.

The present invention relates to a composition for the prevention or treatment of diabetes comprising a long-acting insulin conjugate and a long-acting insulinotropic peptide conjugate, and a therapeutic method for the treatment of diabetes, and more particularly, concurrent administration of the long-acting insulin conjugate and the long-acting insulinotropic peptide conjugate inhibits weight gain caused by insulin treatment, and vomiting and nausea caused by insulinotropic peptide treatment, and reduces the required dose of insulin, thereby remarkably improving drug compliance. Moreover, each of the long-acting insulin conjugate and the long-acting insulinotropic peptide conjugate of the present invention is prepared by linking insulin or insulinotropic peptide with an immunoglobulin Fc region via a non-peptidyl linker, thereby showing improved in-vivo duration of efficacy and stability.

The invention relates to a method for preparing sugar-responsive monodisperse polymer hollow microspheres containing functional group aldehyde groups and phenylboronic acid. The polymer hollow microspheres are the copolymerization of functional monoolefin monomers and polyene monomers containing aldehyde groups and carboxyl groups, and the hollow microspheres are modified with phenylboronic acid; in the presence of silica templates, the functional monoolefin mono A series of polymer microspheres with different inner diameters, different wall thicknesses, and different ratios of aldehyde groups and carboxyl groups were prepared by copolymerization of polyene monomers and cross-linking agents, and the acylation reaction between carboxyl groups and aminophenylboronic acid was used to prepare polymers with different degrees of phenylboronic acid modification. hollow microspheres. The invention has the advantages of simple conditions, convenient operation, easy control of the polymer cavity, easy adjustment of the sugar response range and performance of the polymer hollow microspheres, and the like. The sugar-responsive polymer hollow microspheres prepared by the invention can be applied to the controllable release of insulin, and have a good application prospect as a carrier of insulin for the treatment of diabetes.

The optimal insulin to be delivered by an insulin infusion pump is determined by using a reinforcement learning algorithm aiming to the personalized glucose regulation. The algorithm optimizes the daily basal insulin rate and insulin: carbohydrate ratio for each patient, on the basis of his / her measured glucose profile. The proposed algorithm is able to learn in real-time patient-specific characteristics captured in the daily glucose profile and provide individualized insulin treatment. An automatic and personalized tuning method contributes in the optimisation of the algorithm's performance.